Subtopic Deep Dive
Cylindromatosis Gene Mutations
Research Guide
What is Cylindromatosis Gene Mutations?
Cylindromatosis gene mutations refer to germline and somatic alterations in the CYLD tumor suppressor gene that cause familial cylindromatosis, Brooke-Spiegler syndrome, and multiple familial trichoepithelioma through loss of deubiquitinase activity.
CYLD mutations lead to multiple benign skin appendage tumors such as cylindromas, spiradenomas, and trichoepitheliomas. Bignell et al. (2000) identified CYLD as the familial cylindromatosis gene (664 citations). Over 20 key papers document genotype-phenotype analyses and signaling dysregulation.
Why It Matters
CYLD mutations dysregulate NF-κB and Wnt/β-catenin pathways, driving adnexal tumorigenesis in hereditary syndromes (Trompouki et al., 2003; 959 citations; Tauriello et al., 2010; 217 citations). Insights guide genetic counseling and screening for Brooke-Spiegler syndrome families (Bowen et al., 2005; 141 citations). Therapeutic targeting of deubiquitinase loss informs skin cancer prevention (Blake and Toro, 2009; 104 citations).
Key Research Challenges
Genotype-Phenotype Correlation Absence
No clear link exists between CYLD mutation types and tumor phenotypes in Brooke-Spiegler syndrome or familial cylindromatosis (Bowen et al., 2005; 141 citations). Frameshift and nonsense mutations occur across syndromes without predictive patterns. This hinders prognosis and risk stratification (Blake and Toro, 2009; 104 citations).
Deubiquitinase Activity Mechanisms
Loss of CYLD's K63-linked deubiquitination promotes NF-κB and JNK signaling in tumors (Trompouki et al., 2003; 959 citations; Reiley et al., 2004; 149 citations). Exact substrates and pathway interactions remain incompletely mapped. Functional assays are needed for mutation impacts (Stegmeier et al., 2007; 130 citations).
Tumor Progression Models
Benign adnexal tumors rarely progress to malignancy, but CYLD loss enhances Wnt signaling via Dvl ubiquitination (Tauriello et al., 2010; 217 citations). Models for malignant transformation in spiradenocylindrocarcinomas are lacking. Clinical-pathologic correlations require expansion (Alsaad et al., 2006; 194 citations).
Essential Papers
CYLD is a deubiquitinating enzyme that negatively regulates NF-κB activation by TNFR family members
Eirini Trompouki, Eudoxia Hatzivassiliou, Theodore Tsichritzis et al. · 2003 · Nature · 959 citations
Identification of the familial cylindromatosis tumour-suppressor gene
Graham R. Bignell, William Warren, Sheila Seal et al. · 2000 · Nature Genetics · 664 citations
Loss of the Tumor Suppressor CYLD Enhances Wnt/β-Catenin Signaling through K63-Linked Ubiquitination of Dvl
Daniele V. F. Tauriello, Andrea Haegebarth, Ineke Kuper et al. · 2010 · Molecular Cell · 217 citations
Skin adnexal neoplasms—part 1: An approach to tumours of the pilosebaceous unit
Khaled O. Alsaad, Nidal A. Obaidat, Danny Ghazarian · 2006 · Journal of Clinical Pathology · 194 citations
Skin adnexal neoplasms comprise a wide spectrum of benign and malignant tumours that exhibit morphological differentiation towards one or more types of adnexal structures found in normal skin. Most...
Negative Regulation of JNK Signaling by the Tumor Suppressor CYLD
William W. Reiley, Minying Zhang, Shao-Cong Sun · 2004 · Journal of Biological Chemistry · 149 citations
CYLD is a tumor suppressor that is mutated in familial cylindromatosis, an autosomal dominant predisposition to multiple tumors of the skin appendages. Recent studies suggest that transfected CYLD ...
Mutations in the CYLD gene in Brooke–Spiegler Syndrome, Familial Cylindromatosis, and Multiple Familial Trichoepithelioma: Lack of Genotype–Phenotype Correlation
Sarah Bowen, Melissa Gill, David A. Lee et al. · 2005 · Journal of Investigative Dermatology · 141 citations
The tumor suppressor <i>CYLD</i> regulates entry into mitosis
Frank Stegmeier, Mathew E. Sowa, Grzegorz Nalepa et al. · 2007 · Proceedings of the National Academy of Sciences · 130 citations
Mutations in the cylindromatosis ( CYLD ) gene cause benign tumors of skin appendages, referred to as cylindromas. The CYLD gene encodes a deubiquitinating enzyme that removes Lys-63-linked ubiquit...
Reading Guide
Foundational Papers
Start with Bignell et al. (2000; 664 citations) for CYLD discovery and Trompouki et al. (2003; 959 citations) for deubiquitinase/NF-κB function, as they establish genetic and mechanistic bases.
Recent Advances
Study Bowen et al. (2005; 141 citations) for mutation correlations and Blake and Toro (2009; 104 citations) for deubiquitination signaling updates in syndromes.
Core Methods
Sequencing for germline mutations; ubiquitination assays for NF-κB/JNK/Wnt pathway activity; histopathology for adnexal tumor classification (Alsaad et al., 2006).
How PapersFlow Helps You Research Cylindromatosis Gene Mutations
Discover & Search
Research Agent uses searchPapers and citationGraph on 'CYLD mutations Brooke-Spiegler' to map 20+ papers from Bignell et al. (2000; 664 citations) to recent updates, revealing NF-κB clusters. exaSearch uncovers low-citation genotype studies; findSimilarPapers links Tauriello et al. (2010) Wnt work to adnexal tumors.
Analyze & Verify
Analysis Agent applies readPaperContent to Trompouki et al. (2003) for deubiquitinase details, then verifyResponse (CoVe) checks NF-κB claims across 10 papers with GRADE grading for high evidence on pathway inhibition. runPythonAnalysis parses mutation datasets from Bowen et al. (2005) for statistical correlation tests using pandas.
Synthesize & Write
Synthesis Agent detects gaps in genotype-phenotype links from Blake and Toro (2009), flags NF-κB/Wnt contradictions, and uses exportMermaid for signaling diagrams. Writing Agent employs latexEditText, latexSyncCitations for CYLD review manuscripts, and latexCompile for publication-ready outputs.
Use Cases
"Run statistical analysis on CYLD mutation types vs tumor phenotypes from Bowen 2005 and Blake 2009"
Analysis Agent → readPaperContent (extract mutation tables) → runPythonAnalysis (pandas grouping, chi-square tests on frameshift/nonsense vs cylindroma/spiradenoma) → GRADE-verified correlation report with p-values.
"Draft LaTeX review on CYLD NF-κB dysregulation with citations from Trompouki 2003"
Synthesis Agent → gap detection (signaling gaps) → Writing Agent → latexEditText (pathway section) → latexSyncCitations (add Trompouki/Reiley) → latexCompile (PDF with figure) → output formatted review.
"Find code for CYLD deubiquitinase ubiquitination simulations"
Research Agent → paperExtractUrls (Stegmeier 2007) → paperFindGithubRepo (ubiquitin models) → githubRepoInspect (mitosis entry scripts) → runPythonAnalysis (test Wnt/Dvl ubiquitination code) → verified simulation notebook.
Automated Workflows
Deep Research workflow scans 50+ CYLD papers via searchPapers → citationGraph → structured report on mutation spectra (Bignell 2000 to Zhang 2004). DeepScan applies 7-step CoVe to verify Wnt enhancement claims (Tauriello 2010) with GRADE checkpoints. Theorizer generates hypotheses on CYLD-JNK links (Reiley 2004) for adnexal progression models.
Frequently Asked Questions
What defines Cylindromatosis gene mutations?
CYLD germline mutations cause autosomal dominant skin appendage tumors in familial cylindromatosis and Brooke-Spiegler syndrome via deubiquitinase loss (Bignell et al., 2000).
What methods study CYLD function?
Deubiquitination assays measure K63-chain removal from NF-κB components; mutation screening uses sequencing in families (Trompouki et al., 2003; Bowen et al., 2005).
What are key papers?
Bignell et al. (2000; 664 citations) identified CYLD; Trompouki et al. (2003; 959 citations) showed NF-κB regulation; Bowen et al. (2005; 141 citations) analyzed mutations.
What open problems exist?
Genotype-phenotype correlations lack clarity; malignant progression mechanisms from benign tumors need models (Blake and Toro, 2009; Tauriello et al., 2010).
Research Cancer and Skin Lesions with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Cylindromatosis Gene Mutations with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers
Part of the Cancer and Skin Lesions Research Guide